Emdocam

Country: Unjoni Ewropea

Lingwa: Ingliż

Sors: EMA (European Medicines Agency)

Ixtrih issa

Ingredjent attiv:

meloxicam

Disponibbli minn:

Emdoka bvba

Kodiċi ATC:

QM01AC06

INN (Isem Internazzjonali):

meloxicam

Grupp terapewtiku:

Horses; Pigs; Cattle

Żona terapewtika:

Oxicams

Indikazzjonijiet terapewtiċi:

CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitits-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders. For the relief of pain associated with equine colic.Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.Cats:Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

Sommarju tal-prodott:

Revision: 9

L-istatus ta 'awtorizzazzjoni:

Authorised

Data ta 'l-awtorizzazzjoni:

2011-08-18

Fuljett ta 'informazzjoni

                                41
B. PACKAGE LEAFLET
42
PACKAGE LEAFLET:
EMDOCAM 20 MG/ML SOLUTION FOR INJECTION FOR CATTLE, PIGS AND HORSES
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder
Emdoka bvba
J. Lijsenstraat 16
B-2321 Hoogstraten
Belgium
Manufacturer responsible for batch release:
Produlab Pharma bv
NL-4941 SJ Raamsdonksveer
The Netherlands
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Emdocam 20 mg/ml solution for injection for cattle, pigs and horses
meloxicam
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS
One ml contains:
ACTIVE SUBSTANCE:
Meloxicam
20 mg
EXCIPIENT:
Ethanol (96%)
150 mg
Clear yellow solution for injection.
4.
INDICATION(S)
Cattle
For use in acute respiratory infection with appropriate antibiotic
therapy to reduce clinical signs in cattle.
For use in diarrhoea in combination with oral re-hydration therapy to
reduce clinical signs in calves of
over one week of age and young, non-lactating cattle.
For adjunctive therapy in the treatment of acute mastitis, in
combination with antibiotic therapy.
For the relief of post-operative pain following dehorning in calves.
Pigs
For use in non-infectious locomotor disorders to reduce the symptoms
of lameness and inflammation.
For adjunctive therapy in the treatment of puerperal septicaemia and
toxaemia (mastitis-metritis-agalactia
syndrome) with appropriate antibiotic therapy.
Horses
43
For use in the alleviation of inflammation and relief of pain in both
acute and chronic musculo-skeletal
disorders.
For the relief of pain associated with equine colic.
5.
CONTRAINDICATIONS
Do not use in horses less than 6 weeks of age.
Do not use in pregnant or lactating mares.
Do not use in animals suffering from impaired hepatic, cardiac or
renal function and haemorrhagic
disorders, or where there is evidence of ulcerogenic gastrointestinal
lesions.
Do not use in case of hypersensitivity to the active substance or to
any of the excipients.
For the treat
                                
                                Aqra d-dokument sħiħ
                                
                            

Karatteristiċi tal-prodott

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Emdocam 20 mg/ml solution for injection for cattle, pigs and horses
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One ml contains:
ACTIVE SUBSTANCE:
Meloxicam
20 mg
EXCIPIENT:
Ethanol
150 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear yellow solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle, pigs and horses.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Cattle
For use in acute respiratory infection with appropriate antibiotic
therapy to reduce clinical signs in cattle.
For use in diarrhoea in combination with oral re-hydration therapy to
reduce clinical signs in calves of
over one week of age and young, non-lactating cattle.
For adjunctive therapy in the treatment of acute mastitis, in
combination with antibiotic therapy.
For the relief of post-operative pain following dehorning in calves.
Pigs
For use in non-infectious locomotor disorders to reduce the symptoms
of lameness and inflammation.
For adjunctive therapy in the treatment of puerperal septicaemia and
toxaemia (mastitis-metritis-agalactia
syndrome) with appropriate antibiotic therapy.
Horses
For use in the alleviation of inflammation and relief of pain in both
acute and chronic musculo-skeletal
disorders.
For the relief of pain associated with equine colic.
4.3
CONTRAINDICATIONS
See also section 4.7.
Do not use in horses less than 6 weeks of age.
Do not use in animals suffering from impaired hepatic, cardiac or
renal function and haemorrhagic
disorders, or where there is evidence of ulcerogenic gastrointestinal
lesions.
3
Do not use in case of hypersensitivity to the active substance or to
any of the excipients.
For the treatment of diarrhoea in cattle, do not use in animals of
less than one week of age.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Treatment of calves with Emdocam 20 minutes before dehorning reduces
post-operative pain. Emdocam
alone will not provide adequate pain relief dur
                                
                                Aqra d-dokument sħiħ
                                
                            

Dokumenti f'lingwi oħra

Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Bulgaru 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Bulgaru 16-06-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Spanjol 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Spanjol 16-06-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ċek 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ċek 16-06-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Daniż 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Daniż 16-06-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ġermaniż 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ġermaniż 16-06-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ġermaniż 18-11-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Estonjan 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Estonjan 16-06-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Estonjan 18-11-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Grieg 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Grieg 16-06-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Franċiż 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Franċiż 16-06-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Franċiż 18-11-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Taljan 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Taljan 16-06-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Latvjan 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Latvjan 16-06-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Litwanjan 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Litwanjan 16-06-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Litwanjan 18-11-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ungeriż 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ungeriż 16-06-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ungeriż 18-11-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Malti 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Malti 16-06-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Olandiż 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Olandiż 16-06-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Olandiż 18-11-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Pollakk 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Pollakk 16-06-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Portugiż 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Portugiż 16-06-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Portugiż 18-11-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Rumen 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Rumen 16-06-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Slovakk 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Slovakk 16-06-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Sloven 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Sloven 16-06-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Finlandiż 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Finlandiż 16-06-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Finlandiż 18-11-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Svediż 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Svediż 16-06-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Norveġiż 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Norveġiż 16-06-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Iżlandiż 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Iżlandiż 16-06-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Kroat 16-06-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Kroat 16-06-2021

Fittex twissijiet relatati ma 'dan il-prodott

Ara l-istorja tad-dokumenti